{
    "clinical_study": {
        "@rank": "21613", 
        "arm_group": [
            {
                "arm_group_label": "On-line hemodiafiltration", 
                "arm_group_type": "Experimental", 
                "description": "On-line hemodiafiltration is a type of renal replacement therapy that was assigned as the intervention to compare with the control arm"
            }, 
            {
                "arm_group_label": "High-flux hemodialysis (control)", 
                "arm_group_type": "Active Comparator", 
                "description": "The standard high-flux hemodialysis is the routine renal replacement therapy in sepsis-related acute kidney injury patients and is assigned as the intervention for the control group."
            }
        ], 
        "brief_summary": {
            "textblock": "Following the concept of \"peak concentration hypothesis\", which suggest the cutting peak of\n      pro- and anti-inflammatory mediators would result in restoring a situation of\n      immunohomeostasis. The investigators conducted the prospective randomized controlled trial\n      aimed to compare the clearance efficacy between on-line hemodiafiltration and high-flux\n      hemodialysis in sepsis-related acute kidney injury patients. The lowering cytokines level\n      during sepsis is postulated to improved outcomes in sepsis."
        }, 
        "brief_title": "Efficacy of Online Hemodiafiltrationlysis in Cytokine Removal", 
        "completion_date": {
            "#text": "October 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Sepsis", 
            "Acute Kidney Injury"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acute Kidney Injury", 
                "Sepsis", 
                "Toxemia", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. Blood samples were taken from patients before and at the end of 4-hour in the first\n           dialysis session. The percentage of reductions were calculated from the before and\n           ending samples. The values of postfilter samples were corrected for changes in plasma\n           volume, based on hemoglobin (Hb) of prefilter.\n\n        2. VEGF and other cytokines (IL-6, IL-8, IL-10, and TNF-\u03b1) were determined in the plasma\n           separated from EDTA blood. After collection, plasma separation was achieved by\n           centrifugation for 10 min at 1,500 g. Immediately after separation, the samples were\n           stored at -70 \u00baC until further analysis.\n\n        3. All determinations were carried out in duplicate. The panels of cytokines (VEGF, IL-6,\n           IL-8, IL-10, and TNF-\u03b1) were measured using the Luminex xMap-based multiplex\n           technology. Assays were performed using the MILLIPLEX MAP (multi-analyte panels) 5-plex\n           Cytokine Kit (Millipore, Billerica, MA) on the Luminex\u00ae instrument according to the\n           manufacturer's procedure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Sepsis\n\n          -  acute kidney injury (RIFLE classification F)\n\n          -  Age more than 18\n\n        Exclusion Criteria:\n\n          -  Hemodynamic instability\n\n          -  Whom written informed consent could not be obtained"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 11, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791712", 
            "org_study_id": "KJWW367/53"
        }, 
        "intervention": [
            {
                "arm_group_label": "On-line hemodiafiltration", 
                "description": "pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min", 
                "intervention_name": "On-line hemodiafiltration", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "Nikkiso dialysis machine", 
                    "ARROW dual lumen dialysis catheter", 
                    "PureFlux -150H synthetic membrane dialyzer"
                ]
            }, 
            {
                "arm_group_label": "High-flux hemodialysis (control)", 
                "description": "blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min", 
                "intervention_name": "High-flux Hemodialysis", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Endothelial Growth Factors"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10330"
                }, 
                "name": "King Chulalongkorn Memorial Hospital"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "Enhanced Vascular Endothelial Growth Factor and Pro-inflammatory Cytokine Clearances With On-line Hemodiafiltration Versus High-flux Hemodialysis in Sepsis-related Acute Kidney Injury Patients", 
        "overall_official": [
            {
                "affiliation": "Chulalongkorn University", 
                "last_name": "Khajohn Tiranathanagul, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chulalongkorn University", 
                "last_name": "Wiwat Chancharoenthana, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Thailand: Ethical Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Reduction in plasma Vascular Endothelial Growth Factor (VEGF)level", 
            "safety_issue": "Yes", 
            "time_frame": "At time 0-hour and 4-hour of the study dialysis session"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791712"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chulalongkorn University", 
            "investigator_full_name": "Khajohn Tiranathanagul", 
            "investigator_title": "Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Intradialytic hypotension", 
                "safety_issue": "Yes", 
                "time_frame": "During 4 hours of the study dialysis session"
            }, 
            {
                "measure": "Renal recovery (at 30 days)", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the renal recovery (dialysis-free) for the 30 days from the first initiation of dialysis"
            }, 
            {
                "description": "mortality during hospital admission", 
                "measure": "Hospital patient mortality", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay (an expected average of 5 weeks)"
            }
        ], 
        "source": "Chulalongkorn University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chulalongkorn University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}